Intra-Cellular Therapies Inc. buy JPMorgan Chase & Co.
Start price
12.06.24
/
50%
€64.00
Target price
12.06.25
€72.03
Performance (%)
11.72%
Price
24.07.24
€71.50
Summary
This prediction is currently active. The prediction currently has a performance of 11.72%. This prediction currently runs until 12.06.25. The prediction end date can be changed by JPMorgan_Chase___Co_ at any time. JPMorgan_Chase___Co_ has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m |
---|---|---|
Intra-Cellular Therapies Inc. | 2.143% | 2.143% |
iShares Core DAX® | -0.612% | 0.567% |
iShares Nasdaq 100 | -3.018% | -3.205% |
iShares Nikkei 225® | -2.647% | 0.330% |
iShares S&P 500 | -1.932% | -1.126% |
Comments by JPMorgan_Chase___Co_ for this prediction
In the thread Intra-Cellular Therapies Inc. diskutieren
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its price target raised by analysts at JPMorgan Chase & Co. from $75.00 to $78.00. They now have an "overweight" rating on the stock.
Ratings data for ITCI provided by MarketBeat
Stopped prediction by JPMorgan_Chase___Co_ for Intra-Cellular Therapies Inc.
Intra-Cellular Therapies Inc.
Start price
Target price
Perf. (%)
€41.80
09.03.23
09.03.23
€54.81
09.03.24
09.03.24
45.22%
10.03.24
10.03.24